A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 1579-1584

  Mizoguchi, Takanori ^a   Ozaki, Mineo ^b   Unoki, Kazuhiko ^c   Dake, Yoshinori ^d   Eto, Takahiko ^e   Arai, Miki ^f  

^a Mizoguchi Eye Clinic   (Japan)

^b Ozaki Eye Clinic   (Japan)

^c Unoki Eye Clinic   (Japan)

^d Dake Eye Clinic   (Japan)

^e Eto Eye Clinic   (Japan)

^f Arai Eye Clinic   (Japan)

Author keywords

Intraocular pressure reduction; Normal tension glaucoma; Responder; Tafluprost 0.005 ; Travoprost 0.004

Indexed keywords

TAFLUPROST; TRAVOPROST;

ADULT; AGED; ARTICLE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG WITHDRAWAL; EYE IRRITATION; FEMALE; HUMAN; INTRAOCULAR PRESSURE; JAPANESE; LOW TENSION GLAUCOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 84867132815     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S33414     Document Type: Article

References (24)

1. The Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498-505.
2. The Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487-497.
3. Iwase A, Suzuki Y, Araie M, et al. The prevalence of primary open-angle glaucoma in Japanese. Ophthalmology. 2004;111:1641-1648.
4. Rulo AH, Greve EL, Geijssen HC, Hoyng PFJ. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology. 1996;103:1276-1282.
5. Drance SM, Crichton A, Mills RP. Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma. Am J Ophthalmol. 1998;125:585-592.
6. Harris A, Migliardi R, Rechtman E, Cole CN, Yee AB, Garzozi HJ. Comparative analysis of the effects of dorzolamide and latanoprost on ocular hemodynamics in normal tension glaucoma patients. Eur J Ophthalmol. 2003;13:24-31.
7. Tomita G, Araie M, Kitazawa Y, Tsukahara S. A three-year prospective, randomized and open comparison between latanoprost and timolol in Japanese normal-tension glaucoma patients. Eye. 2004;18:984-989.
8. Dirks MS, Noecker RJ, Earl M, Roh S, Silverstein SM, Williams RD. A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma. Adv Ther. 2006;23:385-394.
9. Kiuchi T, Motoyama Y, Oshika T. Influence of ocular hypotensive eyedrops on intraocular pressure fluctuation with postural change in eyes with normal-tension glaucoma. Am J Ophthalmol. 2007;143:693-695.
10. Quaranta L, Pizzolante T, Riva I, Haidich A-B, Konstas AGP, Stewart WC. Twenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucoma. Br J Ophthalmol. 2008;92:1227-1231.
11. Suh MH, Park KH, Kim DM. Effect of travoprost on intraocular pressure during 12months of treatment for normal-tension glaucoma. Jpn J Ophthalmol. 2009;53:18-23.
12. Kuwayama Y, Komemusi S. Intraocular pressure lowering effect of 0.0015% tafluprost as compared to placebo in patients with normal tension glaucoma: Randomized, double-blind, multicenter. Phase III study. J Jpn Ophthalmol Soc. 2010;114:436-443.
13. Nomura Y, Nakakura S, Moriwaki M, Takahashi Y, Shiraki K. Effect of travoprost on 24-hour intraocular pressure in normal tension glaucoma. Clin Ophthalmol. 2010;30:643-647.
14. Ang GS, Kersey JP, Shepstone L, Broadway DC. The effect of travoprost on daytime intraocular pressure in normal tension glaucoma: a randomized controlled trial. Br J Ophthalmol. 2008;92:1129-1233.
15. Aung T, Chew PTK, Yip C-C, et al. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2001;131:636-642.
16. Scherer WJ. A retrospective review of non-responders to latanoprost. J Ocular Pharmacol Ther. 2002;18:287-291.
17. Camras CB, Hedman K; US Latanoprost Study Group. Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. J Glaucoma. 2003;12:466-469.
18. Rossetti L, Gandolfi S, Traverso C, et al. An evaluation of the rate of nonresponders to latanoprost therapy. J Glaucoma. 2006;15: 238-243.
19. Fukuda M. Classification and treatment of diabetic retinopathy. Diabetes Res Clin Pract. 1994;24 Suppl:S171-S176.
20. Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology. 2009;116:1243-1249.
21. Hariharan S, Minocha M, Mishra GP, Pal D, Krishna R, Mitra AK. Interaction of ocular hypotensive agents (PGF2 alpha analogs-bimatoprost, latanoprost, and travoprost) with MDR efflux pumps on the rabbit cornea. J Ocul Pharmacol Ther. 2009;25:487-498.
22. Okita RT, Okita JR. Prostaglandin-metabolizing enzymes during pregnancy: characterization of NAD(+)-dependent prostaglandin dehydrogenase, carbonyl reductase, and cytochrome P450-dependent prostaglandin omega-hydroxylase. Crit Rev Biochem Mol Biol. 1996;31(2):101-126.
23. Sakurai M, Higashide T, Takahashi M, Sugiyama K. Association between genetic polymorphisms of the prostaglandin F2α receptor gene and response to latanoprost. Ophthalmology. 2007;114:1039-1045.
24. Liang Y, Woodward DF, Guzman VM, et al. Identification and pharmacological characterized of the prostaglandin FP receptor and FP receptor variant complexes. Br J Pharmacol. 2008;154:1079-1093.